Embattled UK Prime Minister Sir Keir Starmer has put changes to the health service on the legislative programme in today's ...

Boehringer Ingelheim's alliance with digital health company Brainomix on an AI-enabled tool for diagnosing interstitial lung ...

A drug at the heart of AstraZeneca's takeover of Amolyt has hit the mark in a phase 3 trial, but could be undermined by an ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection on GLP-1 agonist semaglutide used for diabetes and weight loss. The court in ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US biotech Perfuse Therapeutic and its novel drug implant for eye diseases. The deal ...

Dr. Martin Makary has resigned from the FDA rather than be let go, according to multiple media reports citing unnamed ...

Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. The Indianapolis-headquartered pharma group pledged ...

In 2022, obesity contributed just 1% of the projected value of pharma industry pipeline, as calculated by Deloitte. Now, its share has rocketed to 25%, grouped around just a few drugs with the ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Using mRNA to stop HIV from hiding away in white blood cells could be the key to developing a way to eradicate the infection, rather than simply managing viral levels in the body. The tantalising ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the ...